Roche’s Andrew Monaghan has swapped pharma for clinical research by moving to Chiltern.
Monaghan, who was global head of safety operations at Roche, take on the role of director of global pharmacovigilance at the clinical research organisation Chiltern.
In this new role, he will lead Chiltern’s pharmacovigilance team and expand the organisation’s global pharmacovigilance offering.
“His strong leadership skills and extensive clinical experience will ensure our clients continue to receive customized and efficient safety solutions to meet their specific product and regulatory requirements, whether with investigational or postmarketed products,” said Dr Sharon Moore, executive VP, global medical and regulatory affairs.
Monaghan has served at Roche since 1997, when he joined as global head of PDO clinical management group.
Prior to this role he was director of regulatory affairs at Pfizer Global Research & Development.